Pathology of inhalational anthrax animal models

Veterinary Pathology

Volumn 47, Issue 5, 2010, Pages 819-830

  Twenhafel, Nancy A ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

animal models; anthrax; Bacillus anthracis; biological warfare agent; inhalational anthrax

Indexed keywords

ANTHRAX VACCINE;

ANIMAL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE AGENT; DISEASE MODEL; EXPOSURE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; VIRULENCE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE AGENTS; DISEASE MODELS, ANIMAL; HUMANS; INHALATION EXPOSURE; VIRULENCE;

ANIMALIA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); CAVIA; MUS; ORYCTOLAGUS CUNICULUS; PRIMATES;

EID: 78649269146     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985810378112     Document Type: Article

References (67)

1. Abramova F., Grinberg L., Yampolskaya O., Walker D.: Pathology of inhalational anthrax in forty-two cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 90:2291-2294, 1993.
2. Albrink WS: Pathogenesis of inhalation anthrax. Bacteriol Rev 25:268-273, 1961.
3. Albrink WS, Brooks SM, Biron RE, Kopel M.: Human inhalation anthrax: a report of three fatal cases. Am J Pathol 36:457-471, 1960.
4. Albrink WS, Goodlow RJ: Experimental inhalation anthrax in the chimpanzee. Am J Pathol 35:1055-1065, 1959.
5. Allerberger F., Grif K., Dierich MP, Wimmer A., Plicka H.: Anthrax inhalation and lethal human infection. Lancet 359:711, 2002.
6. Barnes JM: The development of anthrax following the administration of spores by inhalation. Br J Exp Pathol 28:385-394, 1947.
7. Beall FA, Dalldorf FG: The pathogenesis of the lethal effect of anthrax toxin in the rat. J Infect Dis 116:377-389, 1966.
8. Beall FA, Taylor MJ, Thorne CB: Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 83:1274-1280, 1962.
9. Berdjis CC, Gleiser CA, Hartman HA, Kuehne RW, Gochenour WS: Pathogenesis of respiratory anthrax in Macaca mulatta. Br J Exp Pathol 43:151-524, 1962.
10. Borio L., Frank D., Mani V., Chiriboga C., Pollanen M., Ripple M., Ali S., DiAngelo C., Lee J., Arden J., Titus J., Fowler D., O'Toole T., Masur H., Bartlett J., Inglesby T.: Death due to bioterrorism-related inhalation anthrax: report of 2 patients. J Am Med Assoc 286:2554-2559, 2001.
11. Brachman PS, Kaufman AF, Dalldorf FG: Industrial inhalation anthrax. Bacteriol Rev 30:646-659, 1966.
12. Brittingham KC, Ruthel G., Panchal RG, Fuller CL, Ribot WJ, Hoover TA, Young HA, Anderson AO, Bavari S.: Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol 174:5545-5552, 2005.
13. Cleret A., Quesnel-Hellmann A., Mathieru J., Vidal D., Tournier JN: Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J Immunol 178:7994-8001, 2007.
14. Cote CK, Buzue J., Moody KL, DiMezzo TL, Chapman CE, Welkos SL: Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology 154:619-632, 2008.
15. Cote CK, Rea KM, Norris SL, van Rooijen N., Welkos SL: The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with Bacillus anthracis spores. Microb Pathog 37:169-175, 2004.
16. Cote CK, Rooijen NV, Welkos S.: Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun 74:469-479, 2006.
17. Dixon TC, Meselson M., Guillemin J., Hanna PC: Anthrax. Med Prog 341:815-826, 1999.
18. Duong S., Chiaraviglio L., Kirby JE: Histopathology in a murine model of anthrax. Int J Exp Pathol 87:131-137, 2006.
19. Ezzell JW, Welkos SL: The capsule of Bacillus anthracis: a review. J Appl Microbiol 87:250, 1999.
20. Fang H., Cordoba-Rodriguez R., Lankford CS, Frucht DM: Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells. J Immunol 174:4966-4971, 2005.
21. Fang H., Xu L., Chen TY, Cyr JM, Frucht DM: Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J Immunol 176:6155-6161, 2006.
22. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM: Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247, 2001.
23. Fellows PF, Linscott MK, Little SF, Gibbs P., Ivins BE: Anthrax vaccine efficacy in golden Syrian hamsters. Vaccine 31:1421-1424, 2002.
24. Friedlander AM: Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis 20:335-349, 2000.
25. Friedlander AM: Clinical aspects, diagnosis and treatment of anthrax. J Appl Microbiol 87:303, 1999.
26. Friedlander AM, Little SF: Advances in the development of next-generation anthrax vaccines. Vaccine 5:D28-D32, 2009.
27. Friedlander AM, Welkos SL, Pitt MLM, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P., Lawrence WB: Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167:129-142, 1993.
28. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt MLM, Ezzell JW, Friedlander AM: Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 73:691-702, 1995.
29. Gleiser CA, Berdjis CC, Hartman JA, Gochenour WS: Pathology of anthrax infection in animal hosts. Fed Proc 26:1518-1521, 1967.
30. Gleiser CA, Berdjis CC, Hartman JA, Gochenour WS: Pathology of experimental respiratory anthrax in Macaca mulatta. Br J Exp Pathol 44:416-426, 1963.
31. Glomski IJ, Corre JP, Mock M., Goossens PL: Noncapsulated toxinogenic Bacillus anthracis presents a specific growth and dissemination pattern in naive and protective antigen-immune mice. Infect Immun 75:4754-4761, 2007.
32. Glomski IJ, Dumetz F., Jouvion G., Huerre M., Goossens PL: Inhaled non-capsulated Bacillus anthracis in A/J mice: nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting. Microbes Infect 10:1398-1440, 2008.
33. Glomski I., Piris-Gimenez A., Huerre M., Mock M., Goossens PL: Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog 3:e76, 2007.
34. Goossens PL: Animal models of human anthrax: the quest for the holy grail. Mol Aspects Med 30:467-480, 2009.
35. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH: Quantitative pathology of inhalational anthrax: I. Quantitative microscopic findings. Mod Pathol 14:482-495, 2001.
36. Guarner J., Jernigan JA, Shieh WJ, Tatti K., Flannagan LM, Stephens DS, Popovic T., Ashford DA, Perkins BA, Zaki SR; Inhalational Anthrax Pathology Working Group: Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 163:701-709, 2003.
37. Guidi-Rontani C., Weber-Levy M., Labruyere E., Mock M.: Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 31:9-17, 1999.
38. Heine HS, Bassett J., Miller L., Hartings JM, Ivins BE, Pitt ML, Fritz D., Norris SL, Byrne WR: Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob Agents Chemother 51:1373-1379, 2007.
39. Henderson DW, Peacock S., Belton FC: Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 54:28-36, 1956.
40. Heninger A., Drysdale M., Lovchik J., Hutt J., Lipscomb MF, Koehler TM, Lyons CR: Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun 74:6067-6074, 2006.
41. Jernigan JA, Stephens DS, Ashford DA: Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7:933-944, 2001.
42. Lever MS, Stagg AJ, Nelson M., Pearce P., Stevens DJ, Scott EAM, Simpson AJH, Fulop MJ: Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol 89:171-179, 2008.
43. Lincoln RE, Walker JS, Klein F., Rosenwald AJ, Jones WI: Value of field data for extrapolation in anthrax. Fed Proc 26:1558-1562, 1967.
44. Little SF, Ivins BE, Fellows PF, Friedlander AM: Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65:5171-5175, 1997.
45. Little SF, Knudson GB: Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52:309-512, 1986.
46. Loving CL, Kennett M., Lee GM, Grippe VK, Merkel TJ: Murine aerosol challenge model of anthrax. Infect Immun 75:2689-2697, 2007.
47. Lyons CR, Lovchik J., Hutt J., Lipscomb MF, Wang E., Heninger S., Berliba L., Garrison K.: Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun 72:4801-4809, 2004.
48. Moayeri M., Leppla SH: The roles of anthrax toxin in pathogensis. Curr Opin Microbiol 7:19-24, 2004.
49. Nui MT, Ball R., Woo EJ, Burwen DR, Knippen M., Braun MM, VAERS Working Group: Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine 7:290-297, 2009.
50. Parrino J., Hotchkiss RS, Bray M.: Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg Infect Dis 13:191-198, 2007.
51. Passalacqua KD, Bergman NH: Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. Future Med 1:397-415, 2006.
52. Pomerantsev AP, Staritsin NA, Mockov YuV, Marinin LI: Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15:1846-1850, 1997.
53. Ross JM: On the histopathology of experimental anthrax in the guinea pig. Br J Exp Pathol 36:336, 1955.
54. Ross JM: The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 73:485-494, 1957.
55. Ruthel G., Ribot J., Bavari S., Hoover TA: Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis 189:1313-1316, 2004.
56. Stearns-Kurosawa DJ, Lupu F., Taylor FB Jr, Kinasewit G., Kurosawa S.: Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol 169:433-444, 2006.
57. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA: Development of novel vaccines against anthrax in man. J Biotechnol 44:155-160, 1996.
58. Terra JK, Cote CK, France F., Jenkins AL, Bozue JA, Welkos SL, Levine SM, Bradley KA: Resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol 184:17-20, 2010.
59. Tournier JN, Quesnel-Hellmann A., Cleret A., Vidal DR: Contribution of toxins to the pathogenesis of inhalational anthrax. Cell Microbiol 9:555-565, 2007.
60. Twenhafel NA, Leffel E., Pitt MLM: Pathology of inhalational anthrax infection in the African green monkey. Vet Pathol 44:716-721, 2007.
61. Vasconcelos D., Barnewall R., Babin M., Hunt R., Estep J., Nielsen C., Carnes R., Carney J.: Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 83:1201-1209, 2003.
62. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P., Gamble CS, Twenhafel NA, Ivins BE, Heine HS, Sheeler R., Wright ME, Friedlander AM: Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 103:7813-7816, 2006.
63. Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM: A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 199:336-341, 2009.
64. Welkos SL, Keener TJ, Gibbs PH: Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 51:795-800, 1986.
65. Welkos SL, Trotter RW, Becker DM, Nelson GO: Resistance to the Sterne strain of B anthracis: phagocytic cell responses of resistant and susceptible mice. Microb Pathog 7:15-35, 1989.
66. Welkos SL, Vietri NJ, Gibbs PH: Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid Px02 and chromosome in strain-dependent virulence. Microb Pathog 14:381-388, 1993.
67. Zaucha GM, Pitt MLM, Estep J., Ivins BE, Friedlander AM: The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982-992, 1998.